These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18813833)

  • 21. Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study.
    Erbersdobler A; Isbarn H; Steiner I; Schlomm T; Chun F; Mirlacher M; Sauter G
    Urology; 2009 Nov; 74(5):1169-73. PubMed ID: 19476978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells.
    Nicotera TM; Schuster DP; Bourhim M; Chadha K; Klaich G; Corral DA
    Prostate; 2009 Sep; 69(12):1270-80. PubMed ID: 19475654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy.
    Ohyama C; Hosono M; Nitta K; Oh-eda M; Yoshikawa K; Habuchi T; Arai Y; Fukuda M
    Glycobiology; 2004 Aug; 14(8):671-9. PubMed ID: 15044396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
    Denmeade SR; Nagy A; Gao J; Lilja H; Schally AV; Isaacs JT
    Cancer Res; 1998 Jun; 58(12):2537-40. PubMed ID: 9635575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel splice variants of prostate-specific antigen and applications in diagnosis of prostate cancer.
    Pampalakis G; Scorilas A; Sotiropoulou G
    Clin Biochem; 2008 May; 41(7-8):591-7. PubMed ID: 18222179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen.
    Leinonen J; Wu P; Koivunen E; Närvänen A; Stenman UH
    Scand J Clin Lab Invest Suppl; 2000; 233():59-64. PubMed ID: 11317943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prostate-specific antigen (PSA) in women].
    Kamenov Z; Todorova M; Khristov V
    Vutr Boles; 2001; 33(1):40-7. PubMed ID: 11785088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A quantitative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard.
    España F; Sanchez-Cuenca J; Vera CD; Estelles A; Gilabert J
    J Lab Clin Med; 1993 Dec; 122(6):711-9. PubMed ID: 7504042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
    Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
    Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 6-year analysis of the clinicopathological profile of patients with prostate cancer at the University Hospital of the West Indies, Jamaica.
    Coard KC; Skeete DH
    BJU Int; 2009 Jun; 103(11):1482-6. PubMed ID: 19076136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiangiogenic properties of prostate-specific antigen (PSA).
    Mattsson JM; Laakkonen P; Stenman UH; Koistinen H
    Scand J Clin Lab Invest; 2009; 69(4):447-51. PubMed ID: 19551556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples.
    Tabarés G; Jung K; Reiche J; Stephan C; Lein M; Peracaula R; de Llorens R; Hoesel W
    Clin Biochem; 2007 Mar; 40(5-6):343-50. PubMed ID: 17306785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
    Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
    Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?
    Williams SA; Singh P; Isaacs JT; Denmeade SR
    Prostate; 2007 Feb; 67(3):312-29. PubMed ID: 17143882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel small molecule inhibitors for prostate-specific antigen.
    Koistinen H; Wohlfahrt G; Mattsson JM; Wu P; Lahdenperä J; Stenman UH
    Prostate; 2008 Aug; 68(11):1143-51. PubMed ID: 18500692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ARE-I polymorphism on PSA gene in prostate cancer patients of a Turkish population.
    Kalay E; Ergen A; Narter F; Agaçhan B; Görmüs U; Yigit N; Isbir T
    Anticancer Res; 2009 Apr; 29(4):1395-8. PubMed ID: 19414393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and purification of recombinant active prostate-specific antigen from Escherichia coli.
    Jeong S; Lee SW
    J Microbiol Biotechnol; 2007 May; 17(5):840-6. PubMed ID: 18051307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen.
    Dallas SL; Zhao S; Cramer SD; Chen Z; Peehl DM; Bonewald LF
    J Cell Physiol; 2005 Feb; 202(2):361-70. PubMed ID: 15389580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.